We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
California-based Cell Genesys has announced that the results from a clinical trial of GVAX immunotherapy for prostate cancer in patients with early-stage disease have been published in the journal Clinical Cancer Research.
German drugmaker Boehringer Ingelheim and the FDA have announced updates to the black box warning for Aptivus, a treatment for HIV, after it was linked to multiple fatal cases of brain hemorrhaging.
Japan-based Astellas Pharma has submitted a marketing application for the immunosuppressant FK506 modified release formulation (tacrolimus) to the Pharmaceuticals and Medical Devices Agency with the proposed indication of "suppression of organ rejection in organ transplantation" and "suppression of graft rejection and GVHD in bone marrow transplantation."
Pfizer Inc. (PFE) Monday said it plans to lower the price of some of its drugs, including hypertension drug Norvasc, and other medicines that lost patent protection in Switzerland.
UCB today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion to approve marketing authorisation of Keppra (levetiracetam) as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.
A soon-to-be-released report from Business Communications Company (BCC), estimates that the global bioinformatics market is set to grow at an AAGR (average annual growth rate) of 15.8% to reach
nearly $3 billion by 2010.
BioPartners has failed to bring its second biosimilar product into Europe after the European Agency for the Evaluation of Medicinal Products (EMEA) issued a negative opinion on its hepatitis C drug, citing characterisation, manufacturing and quality control concerns.
The Swiss pharmaceutical market grew 3.5% in 2005, the lowest increase in ten years, and a pace considerably below the global average of 6%, the pharmaceutical industry's trade group Interpharma said Monday.
After fulfilment of local transfer requirements andapproval of all relevant authorities, Clariant has completed the sale of its Pharmaceutical Fine Chemicals unit to TowerBrookCapital Partners, L.P. on June 30th, 2006, for a transaction value of CHF 110 million.